Mesenbio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mesenbio Limited - overview
Established
2021
Location
York, England, UK
Primary Industry
Biotechnology
About
Founded in 2021 and based in York, UK, Mesenbio operates as a biotechnology research company that develops and manufactures mesenchymal stem cell-derived extracellular vesicle therapeutics. In January 2024, Mesenbio raised an undisclosed amount of grant funding from new investor Innovate UK. The company specialises in mesenchymal stem cell-derived extracellular vesicle (EV) treatments to tackle human diseases, specifically inflammatory joint disorders, by exploiting the regenerative and anti-inflammatory capabilities of their products. The firm's Cell Line Extracellular Vesicle Release (CLEVR) approach addresses consistency issues in EV therapies by providing a renewable source of therapeutic extracellular vesicles.
The company's technology contains three flagship cell lines (FT-01, FT-02, and FT-03) as well as a pipeline of treatments for various arthritic disorders. The company intends to use the January 2024 funding to hire additional staff, develop pilot manufacturing processes, secure regulatory approvals, and prepare for the conduct of clinical trials for its arthritis drug.
Current Investors
DSW Ventures, NG Bio, Innovate UK
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.mesenbio.net
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Mesenbio Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.